The Heal.LA initiative develops accessible programs in the Los Angeles region, that accelerate the development of new science & technologies to directly impact the health and wellness of our local & global communities.

Heal.LA’s Bioscience Accelerator will identify, nurture and scale top-notch bioscience enterprises in the Los Angeles region.

Calling startups, scientists, and inventors ready to improve the health of people & our planet:

Larta’s award-winning national virtual acceleration program is now being offered in our hometown, Los Angeles. With the support of Gilead Sciences, Heal.LA has launched its first cohort of four early-stage companies at the Lundquist Institute’s BioLabs incubator.  This 4-month pilot program is designed to identify and accelerate the best possible outcome for each company in its sector.

It will use Larta’s acclaimed methodology and results demonstrated over a long period as a commercialization partner to the National Institutes of Health in the U.S. and a number of regions across the globe.

We will grow the program and intend to call for applications to the next cohort in March 2021.

GET UPDATES & AN INVITATION TO APPLY →

What does Heal.LA’s Bioscience Accelerator offer?

Up to $50,000 in business services and more.

Hands-on guidance on your innovation and business from world-class experts.

Tailored webinars focused on specific areas of growth offered by Larta’s council of experts.

Access to our virtual platform and other valuable resources.

Expert feedback and validation of strategies for market and product fit, collaboration with partners, and fundraising.

Demo Days featuring industry and investors, providing market and investment leads and opportunities through curated private introductions.

Applications will open in March 2021.

To receive information and be updated with the Heal. LA initiative, please click the button below to fill out an information form and someone from our team will be in touch with you.

JOIN US →

Meet our Current Cohort

Non-invasive cancer detected from exhaled breath, blood or saliva

Novel therapeutics of non-toxic nanoparticles to deliver therapeutics with enhanced targeting.

Portable devices using diffuse reflectance spectroscopy (DRS) systems to monitor overall health status.

Diagnostic instrument to rapidly determine the antibiotic resistance of bacteria and fungi causing life-threatening infections.

Our Partners